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Abstract
Radiation myelitis is a rather rare but devastating complication following therapeutic irradiation to neoplasms when
the spinal cord is included within the radiation field. Symptoms of radiation myelitis with the therapeutic doses of
radiation commonly employed are usually delayed and most often appear about 6 to 24 months following irradiation.
So far, no treatment has proved satisfactory.
Transplantation of allogeneic mesenchymal stem cells has been a promising therapy strategy for many disorders in the
central nervous system, such as multiple sclerosis, neuromyelitis optica, and autoimmune encephalomyelitis. The cell-base
therapy has shown to act to limit inflammation of central nervous system, stimulate neurogenesis, protect axons
and promote remyelination. But it has not been established as a therapeutic option for radiation myelitis.
In this report, we describe the outcome of allogeneic umbilical cord-derived mesenchymal stem cell transplantation in
a patient with laryngeal carcinoma who developed radiation-induced myelitis of his spinal cord with characteristic
magnetic resonance imaging changes.
Introduction
Radiation myelitis, while rare, is one of the gravest compli-
cations in radiation therapy. Some reports have attempted
to decrease the incidence of radiation myelitis by minimiz-
ing the total radiation dose and the fraction size [1, 2].
However, few articles have focused on the therapy of radi-
ation myelitis. Up to now, therefore, the treatment of radi-
ation myelitis consists mainly of its prevention; and when
this fails, symptomatic measures are usually employed.
Some cases demonstrated dramatic response to high-dose
steroid treatment [3, 4], but steroids were shown to obtain
temporary remissions or only delay the progression of
radiation myelitis for a short period of time [5]. Further-
more, other cases showed that steroids had no influence
on the progression of disease [6].
Mesenchymal stem cells (MSCs), a subset of nonhe-
matopoietic cells, possess pluripotent features and can
be obtained from different sources such as bone marrow,
umbilical cord (UC), UC blood, and adipose tissue of the
human body. These cells are able to differentiate into
tissues of mesenchymal lineages, including bone, cartil-
age, fat, tendon, muscle, and stroma [7–11]. Recently,
research has shown that MSCs can differentiate into
neural stem cells, mature functional neurons, and glial
cells [12–15], while no data suggest that MSCs can
differentiate into axons. Liu et al. [16], however, have
reported that acellular spinal cord scaffold seeded with
MSCs is able to bridge a spinal cord cavity and promote
long-distance axon regeneration and functional recovery
in spinal cord injury rats. The second property of MSCs
is their capacity for immunomodulation. Emerging
evidence has demonstrated that human MSCs can
inhibit, in a dose-dependent manner, the proliferation
and cytokine production of many allogeneic immune
cells, such as T cells, B cells, natural killer (NK) cells,
and dendritic cells [17–19]. MSCs have also been found
to release a number of soluble immunosuppressive fac-
tors involved in MSC-mediated immunoregulation, such
as indoleamine 2,3-dioxygenase, interleukin (IL)-6 and
HLA-G5 [20]. In addition, their low immunogenicity—due
to their lack of expression of class II major histocompati-
bility complex and costimulatory molecules—makes MSCs
able to escape alloantigen recognition and then unable to
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activate alloreactive T cells. The third important property
of MSCs is their capacity to migrate and home to their
target tissues after infusion, like other stem cells. There is a
hypothesis that they can home into, and adjust their differ-
entiation pathway to, diverse tissue microenvironments
[21]. Animal studies have evaluated that MSCs can migrate
into injured spinal cord tissue through cerebrospinal fluid
and into the brain though peripheral blood [15, 22]. These
properties make MSCs therapeutic potential cells in many
chronic inflammatory demyelinating diseases and other
central nervous system (CNS) diseases. MSCs have so
far been applied successfully in patients with multiple
sclerosis, neuromyelitis optica, and ischemic stroke,
and in animal models of autoimmune encephalomyelitis
[23–27]. In our center, UC MSCs have shown an extra-
ordinarily therapeutic effect in patients with refractory
lupus, inflammatory bowel disease, and rheumatoid
arthritis [28–31]. All of these data suggest that MSCs
may be exerted in the treatment of radiation myelitis.
Method
A 37-year-old male was diagnosed with laryngeal carcin-
oma, underwent total laryngectomy, and subsequently
received more than 30 fractions of focal area radiotherapy
in April 2010, with total radiation doses of 6000 cGy. One
year later, the patient complained of right arm numbness
and weakness, which progressively extended to both
upper extremities and the area below his chest. Mag-
netic resonance imaging (MRI) of the spine demonstrated
an enhanced lesion in the radiation field. Cytology of
cerebrospinal fluid was normal. Four months after onset
of clinical manifestations, leg weakness worsened resulting
in multiple falls and difficulty in walking. Radiation
myelitis was considered. Administration of corticosteroids
(dexamethasone 10 mg/day for 10 days) in local hospitals
partially ameliorated the symptoms. However, 1 month
later the patient suffered progressive worsening of lower
limb numbness and weakness, and additional neurological
symptoms such as absence of bladder sensation and in-
continence emerged during tapering to low-dose steroids
(prednisone 10 mg/day). During the second period in the
local hospital, treatment with the same dose of dexa-
methasone for 2 weeks, ganglioside, and mecobalamine
did not show any beneficial results. The patient was then
transferred to our department for further treatment.
Examination showed reduced power in four extrem-
ities (1 out of 5 on the Medical Research Council scale).
Pain and temperature sensations were lost below the T2
level, while vibration and position sense were preserved.
The remainder of the patient’s general and neurologic
examination was normal. The administration of cortico-
steroid (methylprednisolone 500 mg/day intravenous pulse
therapy) and mecobalamine was started, and omeprazole
was also added. However, there were no improvements in
muscle strength and bladder function after 5 days of
high-dose methylprednisolone, so the dose was tapered
based on the underlying adverse effects and ineffective-
ness of steroids. A regimen of intravenous methylpred-
nisolone 40 mg/day together with omeprazole, aspirin,
and mecobalamine was given on the following days. At
the end of second week of admission, an MRI scan of the
head and neck was taken. The craniocerebral scan was
normal, while radiation myelopathy and radiation osteo-
myelitis was obvious (Fig. 1a): hyperintense signals were
visible within the swollen cord from C4 to C6, with abnor-
mal signal intensity in the vertebral body starting from C2
to T4. We thus turned to umbilical cord-derived mesen-
chymal stem cell transplantation (UC-MSCT), due to the
unresponsiveness of steroid treatment and promising re-
sults for MSC transplantation in the treatment of CNS
disorders.
UC MSCs were prepared by the Stem Cell Center of
Jiangsu Province (Jiangsu Beike Bio-Technology, Taizhou,
Jiangsu, China) as described previously with some modifi-
cation [32, 33]. Fresh UC was obtained from an informed
healthy mother in a local maternity hospital after normal
delivery. First, a 10 ml sample of cord blood was analyzed
for communicable diseases, including hepatitis B virus,
hepatitis C virus, HIV, cytomegalovirus, and syphilis. The
UC was then rinsed twice, and the cord blood was re-
moved during this process. The washed cords were cut
into 1 mm2 pieces and floated in low-glucose Dulbecco’s
modified Eagle’s medium (DMEM) containing 10 % fetal
bovine serum (FBS; Stemcell, Vancouver, Canada). The
pieces of cord were subsequently incubated at 37 °C in a
humidified atmosphere consisting of 5 % CO2. Nonadher-
ent cells were removed by washing. The medium was re-
placed every 3 days after the initial plating. When well-
developed colonies of fibroblast-like cells appeared after
10 days, the cultures were harvested with 0.05 % trypsin/
ethylenediamine tetraacetic acid (Gibco Life Technologies,
Grand Island, NY, USA) and passaged into a new flask for
further expansion. UC MSCs used for treatment were sub-
ject to passing quality control tests, including immuno-
phenotype identification and analysis of differentiation
capacity. Flow cytometric analysis confirmed the cells
expressed CD106, CD105, CD90, CD71, CD44, and CD29,
but not CD34, CD14, CD3, or CD45 (all of the antibodies
and their corresponding isotypes were purchased from BD
Biosciences, San Jose, CA, USA). The capacity of MSCs to
differentiate along adipogenic and osteogenic lineages was
evaluated as described previously [32]. The cells with pur-
ity of more than 95 % at passages 3 were used. Before
transplantation, the cells were washed and the FBS was re-
moved from the culture medium. For the procedure, a
total of 5.2 × 107 cells suspended in 100 ml saline were
slowly infused by a heparinized syringe through the cu-
bital vein of the arm over 30 minutes and 1.1 × 107 cells
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suspended in 10 ml saline were slowly injected intra-
thecally, after informed consent was obtained from the pa-
tient and his family.
Results
No adverse events associated with transplantation were
observed during or immediately after UC-MSCT in the
patient.
Two days post transplantation
Two days after the transplantation, the patient presented
less leg numbness and regained muscle strength of the
four limbs against gravity. Bladder function improved
2 weeks after the transplantation. The patient was then
even able to walk slowly with assistance and he was
discharged from hospital in a stable condition with a
regimen of prednisone 10 mg/day and the neural nutri-
tion medicine.
One month post transplantation
At 1-month follow-up after the transplantation, the pa-
tient displayed good general condition with leg numbness
only. He was able to walk without assistance and his in-
continence was replaced by urgency. Control MRI, taken
6 months later after transplantation, showed obvious re-
gression of the previous enhancing lesions. The swelling
of the spinal cord was reduced significantly (Fig. 1b).
Nine months post transplantation
Nine months after first discharge, the patient was re-
admitted to our center for second progressive leg weak-
ness. He noted rapidly progressive difficulty in rising
from low chairs and climbing stairs. Repeated MRI did
not reveal a new enhancing lesion involving the spinal
cord. He received the same therapy with UC-MSCT,
combined with oral prednisone 20 mg/day. The UC was
obtained from another healthy mother. Therapy was still
well tolerated and his symptoms returned to baseline.
Eighteen months post transplantation
The patient had been followed up for 18 months since
the first transplantation. No severe infections, no local
recurrence or distant metastasis of prior tumor, and no
second tumor occurred. A follow-up MRI scan did not
show new enhanced lesions in the spinal cord (Fig. 1c).
In our case, neurological symptoms of the patient devel-
oped progressively with middle-dose steroid treatment,
and did not improve after 5 days of high-dose steroid
administration, so UC-MSCT was then employed. The
improvement of the clinical and radiographic results
suggested that UC-MSCT might be effective in pa-
tients with radiation myelitis. To our knowledge, this
is the first report about UC-MSCT in treatment for
radiation myelitis.
Discussion
Theories related to the pathogenesis of radiation-induced
CNS lesions fall into two main categories [34, 35]. One
category is necrosis due to the death or reproductive
sterilization of glial cells and axons, while the other is
vascular lesions such as edema, fibrin exudation, and even
thrombosis and hemorrhage. Human autopsy studies
showed different degrees of nonspecific inflammatory
responses, including focal or diffuse infiltration of
lymphocytic infiltration, reactive astrocytosis and micro-
gliosis in injured spinal cord. These responses produce
and release proinflammatory cytokines such as IL-1 and
tumor necrosis factor alpha (TNFα) [36, 37]. In our case,
the improvement of neurological signs and symptoms was
associated with or resulting from UC-MSCT, since treat-
ment with steroids before the transplantation was ineffect-
ive. It is difficult to ascertain the direct role of MSC
transplantation in the treatment of radiation myelitis. We
hypothesize that the possible mechanistic rationale was
mainly based on the abilities of MSCs to promote remyeli-
nation, to inhibit toxic inflammation, and to regenerate
axons and neurons after they migrate into the lesion site,
Fig. 1 Comparison of MRI T2-weighted images of the spinal cord. a MRI before UC-MSCT revealing fresh linear hyperintensities within the swollen
cervical cord from C4 to C6. b At 6-month follow-up, MRI demonstrated obvious regression of the previous lesions. Swelling of the spinal cord
was reduced significantly. c At 18-month follow-up, MRI did not show new enhanced lesions in the spinal cord
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which requires further clinical and basic investigations for
confirmation.
Conclusion
In summary, this case showed that MSC transplantation
might be effective in treatment of radiation myelitis,
although the length of follow-up was short. More clinical
studies are needed to confirm the efficacy.
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